CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization

This comprehensive review examines CAR-NK cell therapy for multiple myeloma, an incurable hematological cancer where natural killer (NK) cell function is often impaired. CAR engineering enhances NK cells, enabling them to effectively target MM-associated antigens, showing promise as an "off-the-shelf" therapeutic strategy. Preclinical data confirms robust anti-myeloma activity, including dual-CAR potential. Numerous clinical trials are evaluating CAR-NK efficacy and safety, despite challenges like immune evasion and persistence.